Short Interest in AngioDynamics, Inc. (NASDAQ:ANGO) Decreases By 11.8%

AngioDynamics, Inc. (NASDAQ:ANGO - Get Free Report) saw a significant decline in short interest during the month of December. As of December 31st, there was short interest totalling 882,000 shares, a decline of 11.8% from the December 15th total of 1,000,000 shares. Based on an average daily trading volume, of 625,200 shares, the days-to-cover ratio is currently 1.4 days.

AngioDynamics Price Performance

NASDAQ ANGO traded down $0.34 on Friday, hitting $12.43. 551,568 shares of the company's stock were exchanged, compared to its average volume of 593,298. The firm has a market cap of $503.04 million, a price-to-earnings ratio of -2.21 and a beta of 0.59. The firm's 50-day moving average price is $8.75 and its two-hundred day moving average price is $7.66. AngioDynamics has a fifty-two week low of $5.26 and a fifty-two week high of $13.13.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last announced its quarterly earnings results on Wednesday, January 8th. The medical instruments supplier reported ($0.04) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.11) by $0.07. The business had revenue of $72.90 million during the quarter, compared to the consensus estimate of $70.93 million. AngioDynamics had a negative net margin of 79.38% and a negative return on equity of 7.26%. The business's revenue was down .1% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.05) EPS. On average, research analysts predict that AngioDynamics will post -0.36 earnings per share for the current fiscal year.

Analyst Ratings Changes

ANGO has been the topic of a number of recent research reports. Canaccord Genuity Group dropped their target price on AngioDynamics from $13.00 to $12.00 and set a "buy" rating on the stock in a report on Friday, October 4th. HC Wainwright boosted their price objective on shares of AngioDynamics from $14.00 to $15.00 and gave the company a "buy" rating in a research note on Friday, January 10th.

Insider Buying and Selling at AngioDynamics

In related news, SVP Warren Nighan, Jr. sold 4,060 shares of the firm's stock in a transaction dated Thursday, January 16th. The stock was sold at an average price of $12.31, for a total transaction of $49,978.60. Following the transaction, the senior vice president now owns 41,817 shares of the company's stock, valued at $514,767.27. This trade represents a 8.85 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. 5.40% of the stock is owned by company insiders.

Institutional Investors Weigh In On AngioDynamics

Several institutional investors have recently modified their holdings of ANGO. SG Americas Securities LLC boosted its position in shares of AngioDynamics by 21.3% in the 4th quarter. SG Americas Securities LLC now owns 16,102 shares of the medical instruments supplier's stock worth $147,000 after buying an additional 2,832 shares in the last quarter. Moody National Bank Trust Division lifted its holdings in shares of AngioDynamics by 70.2% in the fourth quarter. Moody National Bank Trust Division now owns 55,780 shares of the medical instruments supplier's stock valued at $511,000 after purchasing an additional 23,003 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of AngioDynamics by 28.7% in the third quarter. JPMorgan Chase & Co. now owns 553,161 shares of the medical instruments supplier's stock valued at $4,304,000 after purchasing an additional 123,271 shares in the last quarter. Barclays PLC grew its position in shares of AngioDynamics by 81.0% in the third quarter. Barclays PLC now owns 83,582 shares of the medical instruments supplier's stock valued at $651,000 after purchasing an additional 37,394 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in shares of AngioDynamics by 5.1% during the 3rd quarter. Geode Capital Management LLC now owns 960,767 shares of the medical instruments supplier's stock worth $7,477,000 after purchasing an additional 46,409 shares in the last quarter. Hedge funds and other institutional investors own 89.43% of the company's stock.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.